Pull to refresh
Logo
Daily Brief
Following Why Sign Up
FDA grants Aptitude first 510(k) clearance for next-gen Metrix COVID test

FDA grants Aptitude first 510(k) clearance for next-gen Metrix COVID test

New Capabilities

Handheld molecular test moves from emergency authorization to traditional FDA clearance

2 days ago: Aptitude announces FDA 510(k) clearance

Overview

Updated 1 hour ago

The FDA granted Aptitude Medical Systems its first 510(k) clearance for the next-generation Metrix COVID test, a handheld molecular diagnostic for at-home and clinic use. The test delivers roughly three times the analytical sensitivity of the original emergency-authorized version and returns results 30% faster.

The clearance lands as COVID-19 emergency use authorizations for medical devices are set to expire on December 26, 2026. Aptitude is moving its entire respiratory portfolio to traditional clearance, with a COVID/Flu test already under FDA review and RSV, strep, and STI assays in late-stage development.

Why it matters

With COVID EUAs expiring in December 2026, this clearance keeps a decentralized molecular test available for homes and urgent-care clinics.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

30%
Faster results than original EUA test
Improvement in time-to-result for the next-gen Metrix COVID test.
3x
Analytical sensitivity improvement
Approximately three-fold greater sensitivity than the original EUA-authorized version.
1st
Traditional FDA clearance for Aptitude
First 510(k) clearance granted to the company.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

TC
Tyler Chozinski
Head of Scientific and Medical Affairs
Overseeing future clearances for Aptitude's respiratory and infectious disease tests

Organizations Involved

Aptitude Medical Systems
Aptitude Medical Systems
Medical device company
First 510(k) clearance for Metrix COVID test; expanding to other assays

Developer of the Metrix handheld molecular diagnostic platform for decentralized healthcare settings.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulatory agency
Granted 510(k) clearance to Aptitude's next-gen Metrix COVID test

The FDA regulates medical devices in the United States, ensuring safety and effectiveness.
Biomedical Advanced Research and Development Authority
Biomedical Advanced Research and Development Authority
U.S. government agency
Funded development of the next-gen Metrix COVID test

BARDA supports the development of medical countermeasures against public health threats.

Timeline

October 2025 September 2026

3 events Latest: 2 days ago

  1. Aptitude announces FDA 510(k) clearance

    Latest Announcement

    Aptitude publicly announced its first 510(k) clearance for the next-gen Metrix COVID test, with 3x sensitivity and 30% faster results.

  2. FDA finds Metrix substantially equivalent to Cue test

    Regulatory Decision

    The FDA cleared the device, determining it was substantially equivalent to the Cue COVID-19 Molecular Test (DEN220028).

  3. Aptitude submits 510(k) for Metrix COVID test

    Regulatory Filing

    Aptitude filed premarket notification K253453 with the FDA for the next-generation Metrix COVID Test.

Scenarios

1

FDA clears Aptitude's next-gen Metrix COVID/Flu test

Likely Resolves by Dec 26, 2026

Discussed by: Aptitude press release, CLP Magazine

Aptitude's combined COVID/Flu assay is under FDA review. A clearance before the December EUA termination would give clinics a single test for two major respiratory viruses heading into flu season.

2

Metrix platform expands to RSV, strep, and STI testing

Possible Resolves by End of 2027

Discussed by: Aptitude's announced pipeline, CLP Magazine

Aptitude is developing additional assays for respiratory syncytial virus, Streptococcus, and sexually transmitted infections. If these clear FDA review, the handheld Metrix system could become a multipurpose point-of-care molecular platform.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

March 2021

Cue Health's COVID-19 test De Novo authorization (2021)

Cue Health received De Novo classification for its molecular COVID test, a pathway for novel devices to gain traditional FDA clearance. The test became available for at-home use.

Then

Cue's test was one of the first molecular at-home tests on the market.

Now

It set a regulatory precedent and later served as a predicate device for Aptitude's 510(k).

Why this matters now

Cue's De Novo path shows how molecular tests can transition from emergency to traditional authorization, a route Aptitude is now following.

August 2021

Pfizer's Comirnaty BLA approval (2021)

The FDA granted full approval to Pfizer's COVID vaccine, converting its emergency use authorization to a Biologics License Application. This was the first COVID vaccine to receive full approval.

Then

Vaccine distribution continued without interruption as the EUA was replaced by the BLA.

Now

It signaled a broader shift of COVID countermeasures from emergency authorizations to traditional regulatory status.

Why this matters now

Like the vaccine's transition, Aptitude's 510(k) clearance moves a critical COVID tool to permanent FDA approval as the EUA framework ends.

Sources

(6)
+1
Fierce Biotech PR Newswire CLP Magazine FDA Aptitude Medical Systems FDA